16588-06-0

Basic information

• Product Name: 4-CHLORO-3-NITROBENZAMIDE
• Synonyms: 4-chlor-3-nitrobenzamid;BUTTPARK 121\15-25;4-CHLORO-3-NITROBENZAMIDE;3-NITRO-4-CHLOROBENZAMIDE
• CAS NO: 16588-06-0
• Molecular Formula: C₇H₅ClN₂O₃
• Molecular Weight: 200.58
• EINECS: 240-644-1
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 16588-06-0.mol

Chemical Properties

• Melting Point: 148-150°C
• Boiling Point: 315.6 °C at 760 mmHg
• Flash Point: 144.7 °C
• Appearance: /
• Density: 1.52 g/cm³
• Vapor Pressure: 0.000432mmHg at 25°C
• Refractive Index: 1.624
• Storage Temp.: Sealed in dry,Room Temperature
• BRN: 645210
• CAS DataBase Reference: 4-CHLORO-3-NITROBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-3-NITROBENZAMIDE(16588-06-0)
• EPA Substance Registry System: 4-CHLORO-3-NITROBENZAMIDE(16588-06-0)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36-37
• RTECS: CV2465000
• TSCA: Yes
• Hazardous Substances Data: 16588-06-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-CHLORO-3-NITROBENZAMIDE is used as a building block in organic synthesis for the creation of various pharmaceuticals and agrochemicals. Its unique structure allows it to be a versatile component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-CHLORO-3-NITROBENZAMIDE is employed as a reagent in chemical reactions. Its potential applications in this field are being explored due to its reactivity and the possibility of it serving as a precursor for the synthesis of new medicinal compounds.
Used in Chemical Reactions:
4-CHLORO-3-NITROBENZAMIDE is utilized as a reagent in chemical reactions, where its high reactivity is leveraged to facilitate specific transformations or to produce desired products in the synthesis process.
Used in the Production of Pharmaceuticals and Agrochemicals:
As a key component in the manufacturing process, 4-CHLORO-3-NITROBENZAMIDE is used in the production of various pharmaceuticals and agrochemicals, contributing to the development of new and effective products in these industries.

InChI:InChI=1/C7H5ClN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)

Upstream product

• 939-80-0 4-chloro-3-nitrobenzonitrile 
• 38818-50-7 4-chloro-3-nitro-benzoyl chloride 
• 7697-37-2 nitric acid 
• 619-56-7 4-chlorobenzamide 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 74-11-3 para-chlorobenzoic acid 
• 1336-21-6 ammonium hydroxide 
• 50-01-1 guanidine hydrochloride 
• 7664-41-7 ammonia 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 2137975-62-1 4-chloro-3-methoxy-5-nitrobenzamide 
• 506-68-3 bromocyane 
• 63603-09-8 methyl 4-chloro-3-methoxy-5-nitrobenzoate 
• 91367-05-4 methyl 4-chloro-3-methylbenzoate 

Downstream Products

• 857488-34-7 4-methylsulfanyl-3-nitro-benzoic acid amide 
• 860683-98-3 4-ethylsulfanyl-3-nitro-benzoic acid amide 
• 939-80-0 4-chloro-3-nitrobenzonitrile 
• 3544-24-9 3-Aminobenzamide 
• 19694-10-1 4-chloro-3-amino-benzoic acid amide 
• 52118-29-3 5-(3-Nitro-4-chlorphenyl)-1,3,4-oxathiazol-2-on 
• 104272-70-0 3-Nitro-4-phenoxy-benzamide 
• 857489-00-0 3-nitro-4-propylsulfanyl-benzoic acid amide 
• 76838-80-7 3-Amino-4-phenoxy-benzamide 
• 76839-15-1 4-Phenoxy-3-thioureido-benzamide 
• 76841-13-9 3-(Imidazolidin-2-ylideneamino)-4-phenoxy-benzamide 
• 76838-35-2 3-(3-Benzoyl-thioureido)-4-phenoxy-benzamide 
• 857486-17-0 3-amino-4-methylsulfanyl-benzoic acid amide 
• 857486-51-2 4-ethylsulfanyl-3-amino-benzoic acid amide 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists

Stimulator of interferon genes (STING) is an endoplasmic reticulum-localized adaptor protein (STING receptor) that has been shown to be activated by binding to natural cyclic dinucleotide (CDN) ligands and plays a vital role in innate immune sensing of exogenous or endogenous DNA, which then induces type I interferons and other cytokines. In this paper, we described a series of amidobenzimidazole STING agonists with high potency for the STING receptor and presented the relevant structure-activity relationships (SARs). The relative potencies of compounds 16g, 24b, and 24e were measured by a STING competition binding assay. A more thorough study of the effect on the STING signaling pathway demonstrated that three compounds, 16g, 24b, and 24e, significantly increased the protein levels and mRNA levels of IFN-β, CXCL10, and IL-6, and 24b as a representative compound effectively triggered the phosphorylation of STING, TBK1, and IRF3 in both human peripheral blood mononuclear cells (hPBMCs) and WT THP-1 cells. In addition, compound 24b demonstrated impressive antitumor efficacy in mice with established syngeneic colon tumors by intravenous administration. Furthermore, the pharmacokinetic profile of compound 24b was fully evaluated.

STING AGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.

STING HETEROCYCLE AGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.

STING PYRAZOLE AGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.

Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors

We previously identified a series of methylsulfonylnitrobenzoates (MSNBs) that block the interaction of the thyroid hormone receptor with its coactivators. MSNBs inhibit coactivator binding through irreversible modification of cysteine 298 of the thyroid hormone receptor (TR). Although MSNBs have better pharmacological features than our first generation inhibitors (β-aminoketones), they contain a potentially unstable ester linkage. Here we report the bioisosteric replacement of the ester linkage with a thiazole moiety, yielding sulfonylnitrophenylthiazoles (SNPTs). An array of SNPTs representing optimal side chains from the MSNB series was constructed using parallel chemistry and evaluated to test their antagonism of the TR-coactivator interaction. Selected active compounds were evaluated in secondary confirmatory assays including regulation of thyroid response element driven transcription in reporter constructs and native genes. In addition the selected SNPTs were shown to be selective for TR relative to other nuclear hormone receptors (NRs).

BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of benzimidazoles in the treatment of cancer.

Discovery and optimization of CRTH2 and DP dual antagonists

A series of phenylacetic acid derivatives was discovered as CRTH2 antagonists. Modification of the series led to compounds that are also antagonists of DP. Since activation of CRTH2 and DP are believed to play key roles in mediating responses of asthma and other immune diseases, this series was optimized to increase the dual antagonistic activities and improve pharmacokinetic properties. These efforts led to selection of AMG 009 as a clinical candidate.

FUSED HETEROCYCLIC COMPOUND HAVING ANTI-HCV EFFECT

Disclosed is a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of them. (I) (In the formula, A represents N or CH; Het represents any one of the following groups: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k) wherein R0 and R respectively represent a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted aryl or the like; R1 and R2 respectively represent a hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl or the like; p is an integer of 0-3; and R3 represents an optionally substituted alkyl or the like.)

3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH

The present invention relates to a 3-amidinoaniline derivative represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group, a lower alkenyl group etc.; R1 represents a hydrogen atom, a hydroxy group, a lower alkyl group etc.; Y represents a single bond or an oxygen atom; and R2 represents a lower alkyl group or a group represented by the general formula: wherein n represents 1 or 2; and T represents a hydrogen atom or a group represented by the general formula:-C(=NH)-W wherein W represents a lower alkyl group; or a pharmaceutically acceptable salt thereof, which has a potent and selective activated blood coagulation factor X inhibitory activity, and an intermediate for producing both.

Unexpected side products in the tetramethylammonium fluoride-dimethylsulphoxide system

Reactions of chloro- and nitro-aromatics with low water content solutions of TMAF in DMSO can lead to complex product mixtures resulting from activation of DMSO by fluoride and the formation of DMSO-derived products. Also, the system has been shown to give hydrolysis products in addition to the well-known ethers and phenols, with carboxylic acids and benzamides being formed from the attempted fluorodenitration of substituted benzonitriles.